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The mammalian SWitch/Sucrose Non-Fermentable (SWI/SNF) chromatin-remodeling BAF (BRG1/BRM-
associated factor) complex plays an essential role in developmental and pathological processes. We show
that the deletion of Baf155, which encodes a subunit of the BAF complex, in the Tie2(+) lineage (Baf155
(CKO) leads to defects in yolk sac myeloid and definitive erythroid (EryD) lineage differentiation from eryth-
romyeloid progenitors (EMPs). The chromatin of myeloid gene loci in Baf155 CKO EMPs is mostly inacces-
sible and enrichedmainly by the ETS bindingmotif. BAF155 interacts with PU.1 and is recruited to PU.1 target
gene loci together with p300 and KDM6a. Treatment of Baf155 CKO embryos with GSK126, an H3K27me2/3
methyltransferase EZH2 inhibitor, rescues myeloid lineage gene expression. This study uncovers indispens-
able BAF-mediated chromatin remodeling of myeloid gene loci at the EMP stage. Future studies exploiting
epigenetics in the generation and application of EMP derivatives for tissue repair, regeneration, and disease
are warranted.
INTRODUCTION
The mammalian hematopoietic system is established from mul-
tiple embryonic origins. The first tissue to produce blood cells is
the yolk sac, which generates primitive erythroid (EryP) cells and
megakaryocytes (MegPs) presumably from bipotential MegP
erythroid progenitors (pMEPs) (Tober et al., 2007). Although Er-
yPs, which express embryonic globin genes, can be detected
as early as embryonic day 7.25 (E7.25) in the blood islands of
the yolk sac, mature MegP cells are not detected until later,
around E9.5, in the yolk sac (Tober et al., 2007). The primary
function of EryP cells is to provide developing embryos with ox-
ygen and nutrients to accommodate the rapid growth of the em-
bryo. Until recently, hematopoietic stem cells (HSCs) originating
from the hemogenic endothelium of the aorta-gonad-meso-
nephros (AGM) have been thought to initiate definitive hemato-
poiesis. However, this paradigm has been challenged by the
identification of erythromyeloid progenitors (EMPs), which
generate definitive erythroid (EryD) and myeloid cell lineages
before the establishment of HSCs (Hoeffel and Ginhoux, 2018;
McGrath et al., 2015; Ginhoux et al., 2010; Schulz et al., 2012;
Hashimoto et al., 2013; Gomez Perdiguero et al., 2015). EMPs
develop transiently from the Tie2-expressing hemogenic endo-
thelium of the yolk sac around E8.5–E10.5, migrate to the fetal
liver, expand, and provide embryos with EryD and myeloid cells
in fetal life (Chen et al., 2011; McGrath et al., 2015; Gomez Per-
diguero et al., 2015; Palis, 2016). EMPs are ultimately replaced
by HSCs, which generate a full spectrum of blood cells, including
lymphoid cell lineages. The importance of EMPs was realized by
the finding that tissue-resident macrophages originate from
EMPs through monocyte intermediates, although microglia are
believed to originate from yolk sac macrophages (Ginhoux
et al., 2010). Despite the critical establishment of the cellular
origin of tissue-resident macrophages from EMPs, few studies
have examined the molecular mechanisms that regulate myeloid
and EryD differentiation from EMPs.
In eukaryotes, DNA is packaged into nucleosomes and subse-
quent higher-order chromatin structures. As a result, DNA is not
easily accessible for transcriptional machinery. Two funda-
mental mechanisms that allow cells to respond to signals and
trigger gene expression are chromatin remodeling and histone
modification. Transcription factors and other proteins are
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believed to gain access to nucleosome-bound DNA using ATP-
dependent chromatin-modifying and remodeling enzymes,
such as the SWI/SNF complex family (Hargreaves and Crabtree,
2011; Kadoch and Crabtree, 2015). SWI/SNF complexes, by uti-
lizing energy derived from ATP hydrolysis, destabilize histone-
DNA interactions and create an open chromatin state. SWI/
SNF complexes are composed of one core ATPase (Brg1 or
Brm) and distinct paralogous BRG1/BRM-associated factor
(BAF) subunit family members that can interact with cofactors,
including transcription factors. Combinatorial assembly of alter-
native families of subunits confers functional specificity to BAF
complexes in different tissues and cell types (Wu et al., 2009).
A recent study showing that BAF60c, a subunit of BAF critical
for heart development (Lickert et al., 2004), together with
GATA4 and TBX5, can reprogrammesoderm to cardiomyocytes
in the mouse embryo (Takeuchi and Bruneau, 2009) highlights
the fact that SWI/SNF-mediated chromatin remodeling is inte-
gral to the lineage-specific transcriptional network. Notably, en-
forced expression of just one component of the multi-protein
BAF complex, BAF60c, in that study was sufficient to confer line-
age-specific gene regulation.
Although chromatin-remodeling proteins are critical for estab-
lishing cell lineage specification in mammalian development,
functional details of how these proteins affect specific cell line-
age development are still lacking. Gene knockout studies have
demonstrated that BRG1 ATPase and BAF155 are required for
blood and vascular development. Particularly, Brg1- or
Baf155-deficient embryos die around implantation (Bultman
et al., 2000; Kim et al., 2001). The peri-implantation lethality of
Baf155-deficient embryos can be extended to mid-gestation
by Baf155 transgene expression (Baf155/; Tg+). However,
these animals display severe blood vessel formation defects in
the yolk sac around E10.5 (Han et al., 2008). Moreover, Tie2-
Cre; Brg1f/f mice are embryonic lethal because of apoptosis of
EryP and lack of embryonic globin gene expression (Griffin
et al., 2008). Angiogenesis is also defective in these animals.
While these studies demonstrate the critical role of BAF-medi-
ated chromatin remodeling in EryP and angiogenesis, it remains
unclear whether BAF-mediated chromatin remodeling is subse-
quently required for the yolk sac hematopoiesis. In this study, we
determined BAF-mediated chromatin remodeling requirements
from hemogenic endothelium to EMPs and myeloid and EryD
lineage differentiation by deleting Baf155 in the Tie2 lineage.
Our data demonstrate that BAF155-mediated chromatin remod-
eling ofmyeloid and EryD gene loci at the EMP stage is critical for
activation of the myeloid and EryD transcriptional program as
well as myeloid and EryD lineage differentiation.
RESULTS
Baf155 CKO Mice Are Embryonic Lethal, Showing
Defects in Myeloid and EryD Lineage Development
To assess the role of chromatin remodeling in hematopoietic
lineage development downstream of the yolk sac hemogenic
endothelium, we first generated Tie2-Cre;Baf155f/+ mice from
matings between Baf155f/f (Choi et al., 2012) and Tie2-Cre
mice, which have been shown to target the yolk sac hemogenic
endothelium (Chen et al., 2011; Gomez Perdiguero et al., 2015).
We also observed effective tdTomato expression in EryP cells,
endothelial cells, myeloid cells, and microglia in Tie2-Cre;R-
osa-loxp-stop-loxp-tdTomato yolk sac and brain (Figure S1A).
Tie2-Cre;Baf155f/+ mice were then crossed with Baf155f/f mice
to generate Tie2-Cre;Baf155f/f mice (hereafter called Baf155
CKO). We found no live Baf155 CKO mice at weaning (Table
S1). We found no Baf155 CKO embryos with abnormal
morphology up to E9.5. However, at E10.5, some Baf155 CKO
embryos were smaller compared with littermate controls and
displayed occasional hemorrhage around the distal end of the
tail and yolk sac (8 of 49), suggesting abnormal vessel formation.
This is consistent with previous findings thatBrg1 orBaf155 defi-
ciency leads to angiogenesis defects (Griffin et al., 2008; Han
et al., 2008). All Baf155 CKO embryos showed severe growth
retardation and seemingly abnormal gross morphology at
E13.5 (data not shown).
We assessed whether the embryonic lethality in Baf155 CKO
mice was due to hematopoietic defects. Ter119+ erythroid cells
from E9.5 and E10.5 yolk sacs, predominantly EryP cells at this
stage, were present at similar levels in wild-type and Baf155
CKO yolk sacs (Figures 1A and S1B). CD45CD31+ endothelial
cells were also present similarly in wild-type and CKO yolk
sacs (Figures 1A and S1B). Notably, there was a significant
reduction in myeloid cells, CD45+CD11b+, in Baf155 CKO yolk
sacs (Figures 1A and S1B). Yolk sac macrophages, CD45+F4/
80+, as well as microglia of the brain, CD45+CX3CR1+CD11b+,
were also reduced significantly in Baf155 CKO embryos (Figures
1A, S1B, and S1C). Although EryP progenitors from wild-type
littermate control and Baf155 CKO yolk sacs were present simi-
larly, myeloid progenitors and BFU-Es were decreased signifi-
cantly in Baf155 CKO yolk sacs (Figure 1B). Corroborating these
data, expression of myeloid lineage genes, including Irf8,
Cx3cr1, and Fcgr3 (CD16), was reduced significantly in Baf155
CKO yolk sacs (Figures 1C and S1D). However, genes ex-
pressed in the EryP lineage, Klf1, Hbb-bh1, and Hbz, were de-
tected similarly in wild-type and CKO yolk sacs (Figure 1C).
Genes expressed in EMPs, cKit, Gata2, Tal1/Scl, and Myb,
were also detected similarly in E9.5 wild-type (WT) and Baf155
CKO yolk sacs (Figure 1C). GP1bb (CD42c), Mpl, and Itga2b
(CD41), genes expressed in megakaryocytes, were also ex-
pressed similarly inWT and CKO yolk sacs (Figure 1C). These re-
sults suggest that Baf155 deficiency leads to selective defects in
myeloid and EryD lineage development.
EMPs Develop in the Absence of Baf155
The selective myeloid and EryD lineage defects seen in Baf155
CKO yolk sacs might be due to defects in EMP generation. Alter-
natively, EMPs are generated, but their differentiation might be
blocked. To differentiate these two possibilities, we first
analyzed EMPs based on phenotypic markers in Baf155 CKO
yolk sacs. EMPs are enriched in cKIT+CD41+CD16/32+ cells
(McGrath et al., 2015). Because expression of Fcgr3 encoding
CD16 was clearly decreased in Baf155 CKO yolk sacs (Fig-
ure 1C), we reasoned that inclusion of CD16/32 in the EMP anal-
ysis might be inadequate for measuring EMPs from Baf155 CKO
yolk sacs. Indeed, the cKIT+CD16/32+CD41+ or CD16/
32+CD41+ cell population was reduced greatly in Baf155 CKO
yolk sacs (Figure S2). Because cKIT is critical for EMP
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Figure 1. Baf155 CKO Mice Show Defects in Myeloid and EryD Lineage Development
(A) A representative flow cytometry analysis of E10.5 yolk sacs (YS) EryP cells (CD45Ter119+), ECs (CD45CD31+), myeloid cells (CD45+CD11b+), macrophages
(CD45+F4/80+), and brain microglia (CD45+CX3CR1+CD11b+) in wild-type (WT) and Baf155 CKO mice is shown in the top panel. The percentage of each
population is shown in the bottom panel. At least 5 biological replicates in 4 independent experiments for either genotype were analyzed, each representing an
individual YS. Data are presented as mean ± SD. Student’s t test; ns, not significant; ****p < 0.0001.
(B) Distribution of EryP (EryP-CFC), EryD (BFU-E), andmacrophage (Mac-CFC) progenitors from E8.25–E8.5/E9.5WT andBaf155CKOYS cells. E8.25–E8.5 data
from 7WT and 9 Baf155 CKO biological replicates and E9.5 data from 8WT and 3 Baf155 CKO biological replicates representing two independent experiments,
with each replicate consisting of a single YS, are shown. Data are presented as mean ± SD. Student’s t test; **p < 0.005, ****p < 0.0001.
(C) qRT-PCR analysis of the indicated gene expression in E9.5 WT and Baf155 CKO YS cells is shown. Data are presented as mean ± SD. Student’s t test; **p <
0.005, ***p < 0.001.
See also Figure S1.




development (Azzoni et al., 2018), and cKit expression was
similar in WT and CKO yolk sacs (Figure 1C), we sorted cKIT+
cells and evaluated their myeloid and EryD potential compared
with cKIT+CD41+CD16/32+ cells. There was an 80% overlap
between cKIT+ and cKIT+CD16/32+CD41+ cell populations
(data not shown). Although cKIT+ and cKIT+CD41+CD16/32+
cells generated similar levels of BFU-Es, cKIT+ cells generated
slightly more CFU-Es compared with cKIT+CD41+CD16/32+
cells, suggesting that cKIT+ cells also contain more committed
erythroid progenitors (Figure 2A). Slightly more myeloid colonies
were generated from cKIT+CD41+CD16/32+ cells comparedwith
cKIT+ cells, suggesting that cKIT+CD41+CD16/32+ cells also
enrich committed myeloid progenitors (Figure 2A). Importantly,
cKIT+ cells were present at similar levels in WT and Baf155
CKO yolk sacs at E8.5–E10.5 (Figure 2B). However, cKIT+ cells
from E10.5 Baf155 CKO yolk sacs generated significantly fewer
myeloid or BFU-E colonies compared with controls (Figure 2C),
suggesting that EMPs were generated in Baf155 CKO embryos
but thatBaf155CKOEMPs have a block in myeloid and EryD dif-
ferentiation. We assessed whether Baf155 inhibition in EMPs
was sufficient to block myeloid and EryD differentiation. To this
end, we knocked down Baf155 in EMPs by transfecting Baf155
esiRNA into sorted cKIT+ cells. We achieved more than 60%
KD efficiency of Baf155 expression, whereas expression of irrel-
evant genes, such as Pu.1, was unaffected (Figure 2D). Notably,
myeloid and EryD output from EMPs was reduced greatly by
Baf155 knockdown (KD) (Figure 2E), indicating that acute dele-
tion of Baf155 in EMPs is sufficient to inhibit myeloid and EryD
lineage differentiation. These data collectively suggest that
Baf155-mediated chromatin remodeling at the EMP stage is crit-
ical for efficient downstream myeloid and EryD lineage
differentiation.
Single-Cell RNA Sequencing Reveals Myeloid Lineage
Differentiation Defects of Baf155-Deficient EMPs
To better understand the myeloid lineage differentiation block in
Baf155 CKO embryos, we subjected yolk sacs from WT and
Baf155 CKO mice to single-cell RNA sequencing (scRNA-seq).
After filtering out low-quality cells, 722 WT and 791 Baf155
CKO yolk sac cells were chosen for further analysis. t-stochastic
neighbor embedding (t-SNE) was used to visualize the popula-
tions. WT yolk sac cells were clustered into 7 populations based
on similarities of the transcriptome (Figure S3A). High expression
of Kdr, Cdh5, and Pecam1 highlights cluster 5 to be an endothe-
lial cell population (Figure S3B). Two distinct erythroid cell pop-
ulations were visible based on the erythroid lineage markers
Gata1, Klf1, and EpoR (Figure S3C). Expression of Hbb-y,




Figure 2. Baf155 Is Required for Myeloid and EryD Lineage Differentiation from EMPs
(A) Distribution of CFU-E, BFU-E, and myeloid colonies developing from KIT+ and KIT+CD41+CD16/32+ population from WT E10.5 YSs. Data are presented as
mean ± SD. Student’s t test; **p < 0.005, ***p < 0.001; 6 biological replicates.
(B) Flow cytometry analysis of the cKIT+ population per YS fromWT and Baf155 CKO embryos on the indicated embryonic day. E8.5 data (mean ± SD) are from 2
independent experiments. E9.5 and E10.5 data (mean ± SD) are from 6 independent experiments, each representing a single YS. Data are presented as mean ±
SD. Student’s t test.
(C) CFU-E, BFU-E, and myeloid colonies from cKIT+ cells from WT (n = 3) and Baf155 CKO (n = 3) YSs. Data are from 2 independent experiments, with each
replicate consisting of a single or 2 pooled YSs of the same genotype. Data are presented as mean ± SD. Student’s t test; **p < 0.01, ***p < 0.001.
(D) qRT-PCR analysis of the indicated gene expression in cKIT+ cells from E10.5 WT YSs transfected with esiRNA against Baf155 or Egfp. Data are presented as
mean ± SD. Student’s t test; ***p < 0.001; four biological replicates from 3 independent experiments.
(E) CFU-E, BFU-E, and myeloid colonies from cKIT+ cells from E10.5 WT YSs transfected with esiRNA against Baf155 or Egfp. Data are presented as mean ± SD.
Student’s t test; ***p < 0.001. Nine biological replicates from 3 independent experiments.
See also Figure S2.




cluster 2 as primitive and cluster 4 as an EryD cell population
(Figure S3D). We also identified Gm15915, Ccl17, Muc13, and
Gdf3 to be expressed in an EryD-specific manner (Figures S3E
and S3I). Expression of the mature myeloid lineage genes
Trem2, Emr1, Cx3cr1, Csf1r, Irf8, and Cd68 identified cluster 6
as a myeloid cell population (Figures S3F and S3J). Enriched
expression of cKit and Itga2b, encoding CD41, and Cd34 identi-
fied cluster 0 as EMPs (Figure S3G). Expression of Pu.1 (Spi1), a
critical factor for myeloid lineage development, expression was
high in EMPs, and its expression was detected continuously in
the myeloid lineage arm (Figures S3G and S3K). Bcl11a, Myb,
Scl (Tal1), and Gata2 expression was detected in EMPs, and
their expression was detected continuously in the EryD cell clus-
ter (Figure S3K). It is also notable that Baf155 and Cd34 expres-
sion was high in the EMP population (Figure S3M). As we re-
ported recently (Zhao and Choi, 2019), clusters 1 and 3
represent smooth muscle cells and pericytes, based on
Hand1, Hand2, Acta2, Tbx20, and Cd248 expression (Figures
S3H and S3L). Desmin expression separated pericytes (cluster
3) from smooth muscle cells (cluster 1; Figure S3L).
When we overlaid WT and Baf155 CKO scRNA-seq data, we
observed that the transcriptomes of endothelial cells (ECs; Fig-
ure 3A, cluster 7), EryP cells (Figure 3A, clusters 1 and 6), and
smooth muscle cells and pericytes (Figure 3A, clusters 2, 4, 5,
and 8) overlapped each other, indicating that Baf155 deficiency
did not affect their overall transcriptome (Figures 3A–3D). How-
ever, clusters 0 and 3, both expressing EMP genes (Figures 3E
and 3F), showed clear separation between WT and Baf155
CKO yolk sac cells (Figures 3B–3D). Baf155 expression was
clearly absent in cluster 3, indicating that Baf155 was deleted
effectively in this population (Figure 3B). Strikingly, a population
with the mature myeloid gene signature (cluster 9) was readily
visible in WT yolk sacs but absent in Baf155 CKO yolk sacs (Fig-
ures 3E and 3G). A population with the EryD gene signature was
also reduced greatly in Baf155 CKO yolk sacs (Figures 3E and
3H). Intriguingly, although EryD cells were reduced greatly, the
megakaryocytic lineage gene signature was high in the pre-
sumptive Baf155 CKO EryD cell population (Figure 3I). This sug-
gests that the megakaryocytic lineage may be the default
pathway in EryD and megakaryocytic lineage choice and that
chromatin remodeling is also critical for EryD and megakaryo-
cyte lineage bifurcation. Additionally, endothelial genes were still
expressed in the Baf155 CKO EMP cell population (Figure 3J).
These data collectively suggest that chromatin remodeling is
needed at the EMP stage for further differentiation into myeloid
and EryD lineages to occur. The endothelial gene program is
sustained in EMPs when subsequent differentiation is blocked.
Alternatively, termination of the endothelial gene program might
require chromatin remodeling.
Chromatin Accessibility of Myeloid and EryD Gene Loci
Is Reduced Greatly in Baf155 CKO EMPs
So far, the data suggested that Baf155 deficiency leads to
myeloid and EryD differentiation block from EMPs. To better un-
derstand the myeloid lineage differentiation defect in Baf155-
deficient EMPs, we sorted cKIT+ cells, EMP enriched, from WT
and Baf155 CKO yolk sacs (Figure S4A) and assessed
genome-wide chromatin accessibility by assay for transpo-
sase-accessible chromatin using sequencing (ATAC-seq; Buen-
rostro et al., 2013). We identified 103,043 and 143,021 acces-
sible chromatin regions in Baf155 CKO and WT cKIT+ cells,
respectively. Among these ATAC-seq peaks, 7,422 regions
were more accessible in WT than in Baf155 CKO cells, whereas
only 56 regions were more accessible in Baf155 CKO cells than
in WT cells (Figures 4A and 4B). The differentially accessible
genomic regions (DARs) were enriched for the binding motifs
of transcription factors (TFs) such as PU.1, IRF8, AP-1, and
CEBP, whereas 13,213 unaffected accessible genomic regions,
commonly open in CKO andWT EMPs (fold change < 1.1 and p >
0.05), were enriched for the different TF binding motifs, such as
CTCF (Figures 4B, 4C, and S4B). Of the 7,422 DARs specific to
WT EMPs, 3,679 peaks contained PU.1 motifs, whereas 1,472 of
13,213 unaffected peaks contained PU.1 motifs. This suggests
that loss of Baf155 leads to a closed chromatin structure at se-
lective genomic regions. The data also suggest potential inter-
play between ETS factors and BAF-mediated chromatin remod-
eling in activating the myeloid lineage program.
The genes associatedwith selective genomic regionswith loss
of chromatin accessibility in Baf155 CKO EMPs were enriched
for biological functions related to immune responses, including
inflammatory response and myeloid leukocyte activation,
whereas genes with unaffected accessible regions were en-
riched for biological functions different from those (Figure 4D).
Genes under the inflammatory response and myeloid leukocyte
activation categories mainly include myeloid genes such as
Cx3cr1, Trem2,Csf1r, Irf8, Emr1, and Fcgr3 (CD16). Importantly,
chromatin of these gene loci was largely inaccessible in Baf155
CKOEMPs (Figures 4E andS4C), explaining the block ofmyeloid
lineage differentiation. In contrast, EC gene loci, Kdr, Cdh5, and
Esam, were similarly accessible in WT and Baf155 CKO EMPs
(Figure S4D). EMP gene loci, cKit, Itga2b (Cd41), and Cd34,
were also readily accessible in WT and Baf155 CKO EMPs (Fig-
ure S4E). Importantly, although chromatin of erythroid lineage
genes that were commonly expressed in EryP cells was readily
accessible, chromatin of the erythroid lineage genes that were
specifically upregulated in EryD cells, Hbb-bt, Gm15915, and
Gdf3, were not (Figure 4F). These data suggest that BAF155-
mediated chromatin remodeling of myeloid and EryD gene loci
at the EMP stage is necessary for subsequent myeloid and
EryD lineage differentiation.
BAF155 Is Recruited to PU.1 Target Gene Loci
PU.1 is a master ETS factor critical for myeloid lineage develop-
ment. PU.1 regulates its own expression (Chen et al., 1995),
although the mechanisms of this autoregulation have not been
elucidated clearly. Because reduced accessible regions in
Baf155 CKO EMPs are represented predominantly by the ETS
bindingmotif, we assessed whether PU.1 requires the BAF com-
plex for activating themyeloid lineage program. Intriguingly,Pu.1
expression itself was diminished in CKO yolk sacs (Figure 5A).
Chromatin of the Pu.1 locus was less accessible in CKO EMPs
(Figure 5A). Because Baf155 KD in EMPs could block myeloid
and EryD differentiation without affecting Pu.1 expression (Fig-
ures 2D and 2E), we reasoned that diminished expression of
Pu.1 and its target genes in Baf155 CKO yolk sacs could be
due to deficiency of BAF-mediated chromatin remodeling at




Pu.1 and its target gene loci. We first assessed whether BAF155
is recruited to PU.1 target genes.We selected 7 genomic regions
that contain the ETS motif and are differentially accessible in WT
and Baf155 CKO yolk sacs. These include genomic regions that
are associated with the Cx3cr1, Trem2, Csf1r, Irf8, and Cd68
genes (Figure 5B; Table S3). We also selected 2 unaffected
ETS regions, UER1 and UER2, from the 1,472 peaks that contain






Figure 3. scRNA-Seq Data Reveal Myeloid and EryD Differentiation Defects from Baf155-Deficient EMPs
(A) t-SNE projection of all cells, showing 10 different clusters.
(B) Baf155/Smarcc1 expression in all YSs, showing the absence of Baf155 expression in the CKO EMP cell population.
(C) An overlay of scRNA-seq data between WT and Baf155 CKO YSs.
(D) Percentage of cells in each cluster from WT versus Baf155 CKO YSs.
(E) Heatmap showing differentially expressed genes in each cluster.
(F) The EMP signature genes Gata2, Tal1, cKit, Cd34, and Pu.1/Spi1 are similarly expressed in WT and Baf155 CKO EMPs.
(G) A cell population with myeloid lineage signature gene expression (Irf8, Maf, Csf1r, Cx3cr1, and Trem2) is absent in Baf155 CKO YSs.
(H) A cell population with EryD lineage signature genes expression (Gdf3, Muc13, Ccl17, and Gm15915) is significantly lower in Baf155 CKO YSs.
(I) A population with elevated megakaryocyte lineage signature gene expression is increased in Baf155 CKO YS cells.
(J) Endothelial lineage signature genes are still expressed in the Baf155-deficient EMP cell population.
See also Figure S3.




by Baf155 deficiency (Figure 5B; Table S3). Although a signifi-
cant mean enrichment was observed for PU.1 and BAF155 bind-
ing at these PU.1 target gene loci, only BAF155 binding, not
PU.1, was enriched at UER1 and UER2 (Figure 5B). We next
determined whether BAF155 can form a complex with PU.1.







Figure 4. Baf155 CKO EMPs Have Reduced Chromatin Accessibility at the Myeloid and EryD Gene Loci
(A) A Venn diagram of the numbers of ATAC-seq peaks found in Baf155 CKO and WT EMPs.
(B) ATAC-seq signals over 10-kb regions centered on the differentially accessible regions (DARs) with reduced signals in Baf155 CKO EMPs compared with the
WT (left) and the presence of the Spi1/Pu.1 motif in the DARs (right).
(C) Heatmaps of HOMER known TF motif fold enrichment in the DARs and unaffected accessible regions. Gray cells indicate no enrichment found (p > 0.05).
(D) Enriched Gene Ontology (GO) terms and their binomial p values from analyzing the DARswith reduced signals inBaf155CKOEMPs (white) and the unaffected
peaks (red) using GREAT.
(E) Epigenome browser views of representative myeloid gene loci.
(F) Epigenome browser views of representative erythroid gene loci.
See also Figure S4.
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Figure 5. BAF155 Interacts with PU.1 and Is Recruited to Its Target Genes
(A) qRT-PCR analysis of Pu.1 expression (top) and epigenome browser view of the Spi1/Pu.1 locus (bottom) fromWT andBaf155CKOYSs. Data are from at least
two biological replicates for either genotype, with each replicate consisting of an individual YS. Data are presented as mean ± SD. Student’s t test; **p < 0.01.
(B) Epigenome browser views of selected myeloid and negative control genomic regions and unaffected ETS regions between WT and Baf155 CKO YS EMPs
(top panel). Also shown is ChIP-qPCR showing enrichment of PU.1 and BAF155 binding at selected myeloid gene loci (highlighted regions in the top panel, 1–6),
negative control gene loci (highlighted regions in the top panel, 2n and 6n), and unaffected ETS regions (highlighted regions in the top panel, UER1 and UER2) in
E10.5 WT YSs (bottom panel). qPCR primers and genomic locations are provided in Table S2. Data are presented as mean ± SD; n = 3.
(C) Cytoplasmic (Cyt) and nuclear (Nuc) protein input and anti-FLAG and isotype control (IgG1) immunoprecipitation of nuclear extracts from MEFs over-
expressing FLAG-Baf155 and Pu.1. Shown are immunoblots for BAF155, PU.1, BRG1, P300, and UTX (KDM6a).
(legend continued on next page)




line that expresses Flag-Baf155 and Pu.1 orHA-Pu.1. Cells were
then subjected to immunoprecipitation using an antibody
against the FLAG tag, followed by PU.1 or hemagglutinin (HA)
immunoblot. PU.1 was co-immunoprecipitated with BAF155
(Figure 5C). Conversely, when the anti-HA antibody was used
for immunoprecipitation, BAF155 was co-immunoprecipitated
with PU.1 (Figure S5A). As reported previously (Alver et al.,
2017; Narayanan et al., 2015), we additionally found BRG1,
p300, and KDM6a (UTX) to be co-immunoprecipitated with
BAF155, suggesting that PU.1 activates its target genes by form-
ing a transcriptional complex with BAF, p300, and KDM6a.
Because p300 and KDM6a mainly target H3K27, we postulated
that PU.1 target gene loci remain methylated at H3K27 sites in
the absence of BAF155, leading to repression of PU.1 target
gene expression. Indeed, although inaccessible regions in
Baf155 CKO yolk sacs showed higher H3K27me3 levels
compared with WT yolk sacs, H3K27me3 levels were similar at
UER1 and UER2 in WT and CKO yolk sacs (Figure S5B). If this
were truly the case, then we would expect that inhibition of
EZH2, the catalytic subunit of Polycomb repressive complex 2
(PRC2), which methylates H3K27 (Laugesen et al., 2019), might
rescue PU.1 target gene expression in Baf155 CKO yolk sacs.
Thus, we set up matings between Tie2-Cre;Baf155f/+ (father)
and Baf155f/f (mother) mice and injected GSK-126 (an EZH2 in-
hibitor) intraperitoneally into the mother at E8. E9.5 yolk sacs
were collected and subjected to qRT-PCR. Although vehicle
treatment did not affect myeloid lineage gene expression, indi-
cating that the GSK-126 effect would be specific (Figure S5C),
expression of many PU.1 target genes was rescued in Baf155
CKO yolk sacs when EZH2 was inhibited (Figure 5D). Pu.1/
Spi1 expression was also rescued, suggesting the BAF-medi-
ated remodeling mechanism of PU.1 autoregulation. It is worth
noting that GSK-126 treatment led to baseline elevation of
expression of some genes, including Irf8, Itgam, Gata2, Scl,
and cKit (Figures 5D and S5D), suggesting that these genes
are normally repressed by the EZH2-mediated mechanism.
DISCUSSION
Chromatin remodeling by the mammalian BAF complex is
required for the development of multiple lineages during
embryogenesis. Brg1 deletion within the Tie2(+) lineage leads
to defective yolk sac angiogenesis and primitive erythropoiesis.
EryP cell defects in these mice are due to increased apoptosis
and lack of embryonic a- and b-globin gene expression (Griffin
et al., 2008).We show thatBaf155 deletion within the Tie2(+) line-
age also causes angiogenesis defects, as evidenced by hemor-
rhage in some Baf155 CKO mice. However, we found that
embryonic globin gene expression was similar, and EryPs and
their progenitors were present at similar levels in WT and
Baf155CKO yolk sacs. Unexpectedly, Baf155CKOmice display
defective yolk sac myelopoiesis and definitive erythropoiesis.
We attribute the phenotype difference between the two mice,
Tie2-Cre; Brg1f/f and Tie2-Cre; Baf155f/f, to the nature of the
deleted gene. Brg1 encodes for an ATPase that is the core of
the BAF complex, whereas Baf155 encodes a BAF structural
component. Presumably, Baf155 deletion might have delayed
the phenotype’s manifestation to reflect the hematopoietic line-
age hierarchy; i.e., the EC and EryP lineages arise before EMPs,
which generate myeloid and EryD lineages. Intriguingly, we
observed that EC genes were still expressed in Baf155-deficient
EMPs, suggesting that the extinction of previous lineage genes is
necessary for new lineage establishment. Alternatively, the pre-
vious lineage gene loci are still accessible in the absence of the
next lineage gene loci’s active chromatin remodeling. Collec-
tively, these data establish that the BAF complex has a critical
role in myeloid and EryD lineage differentiation from EMPs by re-
modeling the chromatin of the myeloid and EryD lineage gene
loci.
Although chromatin remodeling is critical for developing many
different lineages, it is still unclearwhether andhow the specificity
of the BAF chromatin remodeling complex of the target genes is
achieved. Our data demonstrate that BAF-mediated chromatin
remodeling of myeloid and EryD lineage genes at the EMP stage
is necessary for downstreammyeloid and EryD lineage develop-
ment. We found that DARs inWT and Baf155-deficient EMPs are
enriched predominantly for the ETSmotif. Moreover, BAF155 in-
teracted with PU.1 and was recruited to PU.1 target gene loci.
This strongly argues that the BAF complex’s target gene speci-
ficity is achieved by ETS TFs. Consistent with this idea, recent
studies have shown that AP-1 and ETS motifs are enriched in
enhancer regions sensitive to Smarcb1 loss (Alver et al., 2017).
Moreover, TMPRSS2-ERG, a fusion gene product from a chro-
mosomal translocation in prostate cancer, interacts with the
BAF complex in an ETS-dependent manner (Sandoval et al.,
2018), indicating that the BAF complex is required for ERG-medi-
ated prostate oncogenesis. TheBAF complex has been shown to
interact with p300 and acetylates H3K27 (Alver et al., 2017). The
BAF complex also interacts with KDM6a/6b and demethylates
H3K27 (Narayanan et al., 2015). We also observed that BAF155
forms a complex with p300 and KDM6a. Our data show that
DARs in Baf155 CKO EMPs included mostly PU.1 target genes
and displayed higher H3K27me3 levels. EZH2 inhibitor treatment
could rescue some of the PU.1 target gene expression in Baf155
CKO yolk sacs. These data suggest that PU.1 activates its target
genes by forming a complex with BAF, p300, and KDM6a/6b and
triggering H3K27 acetylation/demethylation of the target genes
(Figure 5E). In the absence of the BAF complex, PU.1 target loci
are occupied by EZH2, suppressing PU.1 target gene expression
(Figure 5E).
(D) qRT-PCR analysis of Cx3cr1, Irf8, Csf-1r, Pu.1/Spi1, Itgam, and Emr1 gene expression in E9.5 WT and Baf155 CKO YSs with or without GSK126 treatment.
Gene expression was normalized to the untreated WT mean value. Data are from at least four biological replicates for either genotype, with each replicate
consisting of an individual YS. Data are presented as mean ± SD. Student’s t test; *p < 0.05, **p < 0.01, ***p < 0.001.
(E) A model showing BAF-mediated chromatin remodeling in PU.1 transcriptional gene activation.
See also Figure S5.




Reduced Pu.1 expression leads to acute myeloid leukemia
(Will et al., 2015; Steidl et al., 2007). Moreover, Pu.1 activation
in hematopoietic stem and progenitor cells can lead to myeloid
lineage skewing and deregulated hematopoiesis in chronic in-
flammatory conditions (Pietras et al., 2016; Etzrodt et al.,
2019). Methylation of BAF155 at the R1064 residue by coactiva-
tor-associated arginine methyltransferase 1 (CARM1; also
known as PRMT4) is critical for tumor progression and metas-
tasis (Wang et al., 2014). Although CARM1 is essential for
myeloid leukemogenesis, it is dispensable for normal hemato-
poiesis (Greenblatt et al., 2018). UTX (KDM6a) suppresses
myeloid leukemogenesis partially by repressing an ETS-medi-
ated transcriptional program (Gozdecka et al., 2018). Kdm6b is
required for fetus-derived T-ALL and adult-derived AML (Malla-
ney et al., 2019). These studies collectively suggest that control-
ling Pu.1 expression and its activity might be critical for manag-
ing cancer and chronic inflammatory diseases. Intriguingly, ETS
factors can regulate Baf155 expression (Ahn et al., 2005), sup-
porting an interplay between ETS TFs and BAF expression and
function. Future studies delineating the crosstalk between ETS
factors and BAF and interaction among BAF, p300, PU.1, and
KDM6a/6b and PU.1 target gene expression will be critical for
further understanding myeloid lineage and leukemia develop-
ment. Future applications of the epigenetics involving PU.1
and BAF155 expression and function for tissue repair, regenera-
tion, and diseases are warranted.
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Anti-mouse CDD45-APC (Clone 30-F11) BioLegend Cat#103112; RRID:AB_312977




Anti-mouse CD31-Biotin (Clone MEC13.3) BioLegend Cat#102504; RRID:AB_312911







Anti-mouse F4/80-PE (Clone BM8) BioLegend Cat#123110; RRID:AB_893486
Anti-mouse F4/80-APC (Clone BM8) BioLegend Cat#123116; RRID:AB_893481
Anti-mouse CX3CR1-PE (Clone SA011F11) BioLegend Cat#149006; RRID:AB_2564315
Anti-mouse CD117(c-Kit)-PE (Clone 2B8) BioLegend Cat#105807; RRID:AB_313216
Anti-mouse CD117(c-Kit)-APC (Clone 2B8) BioLegend Cat#105812; RRID:AB_313221
Anti-mouse CD41-APC (Clone MWReg30) BioLegend Cat#133914; RRID:AB_11125581
Anti-mouse CD16/32-BV421 (Clone 93) BioLegend Cat#101331; RRID:AB_2562188
Anti-mouse CD16/32-PE (Clone 2.4G2) BD Biosciences Cat#553145; RRID:AB_394660
Purified anti-mouse CD16/32 (Clone 93) BioLegend Cat# 101302; RRID:AB_312801
BV421-Streptavidin BioLegend Cat#405225 (No RRID number available)
BV605-Streptavidin BD Biosciences Cat#563260 (No RRID number available)
SMARCC1/BAF155 (D7F8S) Rabbit mAb
antibody
Cell Signaling Tech. Cat#11956; RRID:AB_2797776
PU.1 (9G7) Rabbit mAb antibody Cell Signaling Tech. Cat# 2258; RRID:AB_2186909
p300 (D8Z4E) Rabbit mAb antibody Cell Signaling Tech. Cat# 86377; RRID:AB_2800077
Brg1 (D1Q7F) Rabbit mAb antibody Cell Signaling Tech. Cat# 49360; RRID:AB_2728743
UTX (D3Q1I) Rabbit mAb antibody Cell Signaling Tech. Cat# 33510; RRID:AB_2721244
HA-Tag(C29F4) Rabbit mAb antibody Cell Signaling Tech. Cat# 3724; RRID:AB_1549585
Rabbit IgG Cell Signaling Tech. Cat#2729; RRID:AB_1031062
Rabbit Anti-Histone H3, trimethyl (Lys27)
Polyclonal antibody
Millipore Cat# 07-449; RRID:AB_310624
Monoclonal ANTI-FLAG M2 antibody Sigma-Aldrich Cat# F3165; RRID:AB_259529
EZview Red ANTI-FLAG M2 Affinity Gel Sigma-Aldrich Cat# F2426; RRID:AB_2616449
EZview Red Anti-HA Affinity Gel Sigma-Aldrich Cat# E6779; RRID:AB_10109562
Bacterial and Virus Strains
One Shot Stbl3 Chemically Competent
E.Coli
Thermo Fisher Scientific Cat#C737303
Chemicals, Peptides, and Recombinant Proteins
DMEM GIBCO Cat#11965092
FBS Atlanta Biologicals Cat#S12450
L-Glutamine GIBCO Cat#35050061
MEM Non-Essential Amino Acids Corning Cat#25-025-Cl
MEM Sodium Pyruvate Corning Cat#25-000-Cl
Geneticin GIBCO Cat#10131-035
(Continued on next page)





REAGENT or RESOURCE SOURCE IDENTIFIER
Puromycin Sigma Cat#P8833
Blasticidin S Hydrochloride Research Products International Corp Cat#B12200
penicillin-streptomycin GIBCO Cat# 15140122
IMDM GIBCO Cat#2440046
Hexadimethrine bromide Sigma Cat#H9268
Interleukin-3 (IL-3) supernatant This paper N/A




IL-11 R&D Systems Cat#418-ML
Erythropoietin (EPO) PeproTech Cat#100-64
Lipofectamine 3000 Thermo Fisher Scientific Cat#L3000-001
esiBaf155 Sigma Cat#EMU012611-50UG
esiEGFP Sigma Cat#EHUEGFP-50UG
MethoCult3434 Stem Cell Technologies Cat#M3434
GSK-126 MedChem Cat#HY-13470
SBE-b-CD MedChem Cat# HY-17031
DSP (Dithiobis (succinimidyl propionate)) Thermo Fisher Scientific Cat#22585
0.25% trypsin-EDTA GIBCO Cat#25200-056
Protease inhibitor cocktail Sigma Cat#11836170001
Tween 20 Sigma Cat#P9416
Iodoacetamide Sigma Cat#I6125
Sepharose 4B Sigma Cat#4B200
LDS buffer Invitrogen Cat#NP0007
Beta – mercaptoethanol Sigma Cat#444203
ECL chemiluminescence substrate Thermo Fisher Scientific Cat#32106
Collagenase type IV Worthington Cat#LS004188
Deoxyribonuclease I Worthington Cat#LS002139
0.25% Collagenase Stem Cell Technologies Cat#07902
ProteinA-Sepharose 4 Sigma-Aldrich Cat#P9424
Critical Commercial Assays
QuickTiter Lentivirus Associated HIV p24
Titer Kit
Cell Biolabs, INC Cat#VPK-107
SimpleChIP Plus Enzymatic Chromatin IP
Kit
Cell Signaling Tech. Cat#9005
RNeasy Micro/Mini Kit QIAGEN Cat#74004/74106
qScript cDNA SuperMix Quanta Cat#101414-106
DNA Clean and Concentrator 5 Zymo Research Cat#D4014
AMPure XP beads Beckman Coulter N/A
Deposited Data
ATAC-seq data This paper GEO: GSE144243
GRCm10/mm10 UCSC genome browser http://hgdownload.soe.ucsc.edu/
goldenPath/mm10/bigZips/
scRNA-seq data This paper GEO: GSE159381
scRNA-seq data of WT cells Zhao and Choi, 2019 GEO: GSE130146
Experimental Models: Cell Lines
293FT cell line ThermoFisher Cat#R70007
(Continued on next page)






Further information and requests for resources and reagents should be directed to and will be fulfilled by the corresponding author
and Lead Contact, Dr. Kyunghee Choi (kchoi@wustl.edu).
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Platinum-E (Plat-E) retroviral packaging cell
line
Cell Biolabs, INC Cat#RV-101
Mouse Embryonic Fibroblast (MEF) Hansen, T.H. Washington University in St.





MEF-Flag-Baf155+HA-PU.1 This paper N/A
Experimental Models: Organisms/Strains
C57BI6/J Wild Type Jackson Laboratories Stock No:000664
Tie2-Cre Jackson Laboratories Stock No:004128
Baf155f/f Rho Hyun Seong; Choi et al., 2012 N/A
Oligonucleotides




pRRL_CAGpN-Flag-Baf155-IRES-GFP Addgene Cat#24561; RRID:Addgene_24561
CSII-EF-MCS-IRES2-bsr-PU.1-HA This paper N/A
psPAX2 Addgene Cat#12260; RRID:Addgene_12260
pMD2.G Addgene Cat#12259; RRID:Addgene_12259
Pu.1-IRES-mCherry retroviral plasmid DNA Addgene Cat#80140; RRID:Addgene_80140
pLKO.1-puro-Ubc-TurboGFP Sigma Cat#SHC014; (No RRID number available)
Software and Algorithms
FlowJo software version 10.5.3 TreeStar Inc. https://www.flowjo.com
Graphpad Prism version 8.4.3 Graphpad Software, LLC. https://www.graphpad.com/
scientific-software/prism/
Cutadapt version 1.11 Martin, 2011 https://github.com/marcelm/cutadapt/
Bowtie 2 version 2.3.4.1 Langmead and Salzberg, 2012 http://bowtie-bio.sourceforge.net/
bowtie2/index.shtml
MACS2 version 2.1.1 Zhang et al., 2008 https://github.com/macs3-project/MACS
WashU Epigenome Browser Zhou et al., 2011 https://epigenomegateway.wustl.edu/
DiffBind version 2.6.6 Ross-Innes et al., 2012 https://bioconductor.org/packages/
release/bioc/html/DiffBind.html
deepTools Ramı́rez et al., 2016 https://github.com/deeptools/deepTools
GREAT version 4.0.4 McLean et al., 2010 http://great.stanford.edu/public/
html/index.php
HOMER version 4.8 Heinz et al., 2010 http://homer.ucsd.edu/homer/index.html





Seurat version 2.3.4 Seurat https://satijalab.org/seurat/
Other
Fisherbrand Model 120 Sonic
Dismembrator
Fisher scientific N/A





This study did not generate any unique reagents.
Data and Code Availability
The ATAC-seq data discussed in this publication have been deposited in NCBI’s Gene Expression Omnibus and are accessible
through GEO Series accession number GSE144243 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE144243).
The accession number for the scRNA-Seq data reported in this paper is GEO: GSE159381.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
Tie2-Cre;Baf155 CKO mice were obtained by first crossing Tie2-Cre (Stock No: 4128, Jackson Labs) males (2-3 months old) to
Baf155f/f (Choi et al., 2012) females (2-3 months old) to generate Tie2-cre; Baf155f/+ mice. Next, timed matings using Tie2-Cre;
Baf155f/+ males (2-8 months old) and Baf155f/f females (2-3 months old) were set up in the evening and females checked for vaginal
plugs the following morning (12pm = E0.5). Females were separated from males and housed in the animal barrier until the desired
time point. Females were euthanized using CO2 asphyxiation and uteri removed for embryo collection. Embryos and collected tissue
were kept on ice in PBS with 10% FBS until processed for analysis. Wild-type (WT) littermates were used as controls. Animal hus-
bandry, generation, and handling were performed in accordance with protocols approved by the Institutional Animal Care and Use
Committee of Washington University School of Medicine in St. Louis.
Cell culture and transduction
The Mouse Embryonic Fibroblast (MEF) cell line has been previously described (Lybarger et al., 2003). MEF and MEF-derived stable
cell lines were cultured in Iscove’s Modified Dulbecco’s Medium (IMDM) (2440046, GIBCO) supplemented with 10% (v/v) Fetal
bovine serum (FBS) (S12450, Atlanta Biologicals), and 100U/ml penicillin-streptomycin (15140122, GIBCO). MEF cells were trans-
duced with Flag-Baf155-IRES-GFP lentiviral and Pu.1-IRES-mCherry retroviral particles. Hexadimethrine bromide (8 mg/ml)
(H9268, Sigma) was added during transductions to increase viral particle uptake. Transduced cells were sorted twice to ensure
greater than 90%purity.When HA-Pu.1 lentivirus was used,MEF-Flag-Baf155 cells were transducedwith HA-Pu.1 lentiviral particles




The following primers were used to obtain genotype information for breeders and embryos:
Baf155 - TGTCATCCATGAGGAGTGGTC30 (F); 50GGTAGCTCACAAATGCCTGT30 (R); WT = 400 bp; Floxed = 450 bp. Cre -
50ACCAGAGACGGAAATCCATCG30 (F); 50CCACGACCA AGTGACAGCAATG30 (R); Cre = 390 bp.
Lentiviral and retroviral particle production
Baf155 lentiviral plasmid DNA, pRRL_CAGpN-Flag-Baf155-IRES-GFP, was a gift from Jerry Crabtree (Addgene, plasmid# 2456).
MISSION pLKO.1-puro-Ubc-TurboGFP (Sigma, SHC014) was used as a transduction efficiency control. The Pu.1 lentiviral plasmid
was constructed by adding a HA tag at the Pu.1N-terminal and inserting it into the CSII-EF-MCS-IRES2-bsr lentiviral backbone. Len-
tiviral packaging plasmid psPAX2 (Addgene, plasmid# 12260) and VSV-G envelope expressing plasmid pMD2.G (Addgene, plasmid#
12259) were gifts from Didier Trono. For cloning purposes, viral plasmid DNA was transformed using One Shot Stbl3 Chemically
Competent E.Coli (C737303, ThermoFisher). Lentiviral particles were produced using the 293FT cell line (R70007, ThermoFisher),
which was maintained in high glucose Dulbecco’s Modified Eagle Medium (DMEM) (11965092, GIBCO), 10% FBS, 200 mM L-Gluta-
mine (35050061, GIBCO), 10mMMEMNon-Essential Amino Acids (25-025-Cl, Corning), 100mMMEMSodiumPyruvate (25-000-Cl,
Corning), and 500 mg/ml Geneticin (10131-035, GIBCO). Cells were transfected with lentiviral DNA using the calcium phosphate
method. Sixteen hours after transfection, media was replaced and cells were incubated at 37C in 5%CO2 for an additional 48 hours.
Virus titer was determined by QuickTiter Lentivirus Associated HIV p24 Titer Kit (Cell Biolabs, INC). Pu.1-IRES-mCherry retroviral
plasmid DNA was a gift from Ellen Rothenberg (Addgene, plasmid# 80140). Platinum-E (Plat-E) retroviral packaging cell line was
used to generate the Pu.1 retrovirus using the calcium phosphate method. Cells were maintained in high glucose DMEM supple-
mented with 10% FBS, 1 mg/ml puromycin (P8833, Sigma), 10 mg/ml Blasticidin S Hydrochloride (B12200, Research Products Inter-
national Corp), and 100 U/ml penicillin-streptomycin. Media was replaced the following morning and virus harvested 48 hours after
transfection.
esiRNA transfection
E10.5 WT yolk sac (YS) cKIT+ cells (1x104) were plated in 100 mL maturation media (IMDM, 20% FBS, 1% interleukin-3 (IL-3) super-
natant, 10 ng/ml murine stem cell factor (PeproTech), 10 ng/ml M-CSF (PeproTech), 10 ng/ml GM-CSF (PeproTech), 10 ng/ml IL-6,




10 ng/ml IL-11 (R&D Systems) and 2 U/ml erythropoietin (PeproTech) in a 96-well plate and transfected with 300 ng esiRNA against
either Baf155 (Sigma, EMU012611) or Egfp (Sigma, EHUEGFP) with 2 mL lipofectamine 3000 (Thermofisher). Cells were cultured in a
37C incubator with 5%CO2 for 36-48 hours and then subjected to either RNA extraction or re-plating in methylcellulose (MethoCult
3434, Stem Cell Technologies).
Hematopoietic progenitor assays
Methylcellulose colony-forming assays were performed using MethoCult 3434 (Stem Cell Technologies). E10.5 WT YS were pooled
and sorted for either cKIT+ or cKIT+CD41+CD16/32+ populations. Sorted cells weremixed inmethylcellulose (2,000 /ml) and plated in
triplicate using 35mm Petri-dishes. Cultures were maintained in a humidified incubator at 37C, 5% CO2. CFU-E colonies were
counted after 2-3 days of culture. Primitive erythroid, definitive erythroid (BFU-E), macrophage, and granulocyte/macrophage col-
onies were counted following 5-7 days of culture.
In vivo GSK-126 treatment
GSK-126 (HY-13470, MedChem) was dissolved in SBE-b-CD (HY-17031, MedChem) at a final concentration of 20 mg/ml. Pregnant
mice (E8) were injected intraperitoneally with equal volumes of either SBE-b-CD (vehicle) or GSK126 (100mg/kg). At E9.5, pregnant
females were euthanized using CO2 asphyxiation and the uteri removed for embryo collection and dissection.
Nuclear extract preparation
Transduced MEF cells expressing Baf155 and Pu.1were treated with DSP (Dithiobis [succinimidyl propionate], Thermo Scientific), a
membrane permeable cleavable crosslinker, before subjected to nuclear extraction. Cells were detached using 0.25% trypsin-EDTA,
washed twice with phosphate-buffered saline (PBS), resuspended in PBS containing 1mMDSP at approximately 1x107/ml, and incu-
bated at room temperature (RT) for 30min. The crosslink reaction was stopped by adding 1M Tris-HCl (pH7.5) at a final concentration
of 20mM for 10min. DSP treated cells after wash were then incubated in hypotonic buffer (25mM HEPES (pH7.6), 25mM KCl, 5mM
MgCl2, 0.05mM EDTA, 0.1% NP40, 5% Glycerol, 1mM PMSF) on ice for 10min, vigorously vortexed for 10 s, and centrifuged at
13,000 xg for 1 min. Supernatant, primarily containing soluble cytosolic protein, was collected for immunoblot while the pellet con-
taining nuclei was resuspended in nuclear extraction buffer (10mM HEPES (pH7.6), 100mM KCl, 3mM MgCl2, 0.1mM EDTA, 5%
Glycerol supplemented with 1mM PMSF and 1X protease inhibitor cocktail (complete mini Roche, 11836170001, Sigma)), incubated
on ice for 15min, and followed by 3x10s of sonication at 50%amplitude. Insoluble proteins and debris were removed from the nuclear
extract by high-speed centrifugation (10 min at 18,000 g).
Immunoprecipitation
Nuclear extract was mixed 1:1 with IP buffer (10 mM Tris-HCl (pH 7.5), 200 mM NaCl, 1 mM EDTA, 0.2% Tween 20, 1X protease
inhibitor cocktail, 20mM Iodoacetamide) and precleared by Sepharose 4B (4B200, Sigma). Immunoprecipitation was performed
by incubating precleared nuclear extract with antibody-bound beads (anti-Flag M2 affinity gel, anti-HA (clone HA-7) affinity gel, or
Protein A as a negative control (Sigma)) at 4C overnight. Precipitates were washed 4 times with washing buffer (10 mM Tris-HCl
(pH 7.5), 150mMNaCl, 0.1% Tween 20, 20mM Iodoacetamide) and eluted in 1X LDS buffer (Invitrogen). DSPwas cleaved by adding
5% beta- mercaptoethanol in LDS loading buffer at 100C for 10 min.
Western blotting
Western blotting was conducted following standard protocols. Primary antibodies used for western blotting are listed in key re-
sources table. Secondary antibodies were horseradish peroxidase-conjugated mouse anti-rabbit IgG light chain and mouse IgG
kappa chain binding protein (Santa Cruz Biotechnology, 1:10,000 dilution). Membranes were developed with ECL chemilumines-
cence substrate (ThermoFisher) and visualized using photographic film.
Chromatin immunoprecipitation (ChIP) coupled with quantitative real-time PCR (ChIP-qPCR)
Chromatin immunoprecipitation (ChIP) was performed according to the manufacture’s protocol (ChIP kit, 9005, Cell Signaling Tech-
nologies) with the following modification: 25mg cross-linked YS tissue was used per preparation. After cell lysis, nuclei extracts were
digested by adding 0.5 mLMicrococcal Nuclease per IP prep and incubating for 20 min at 37Cwith frequent mixing to digest DNA to
a size of approximately 150-900 bp. Digestion was stopped by adding 10 mL 0.5 M EDTA and samples placed on ice for 2 min. Nuclei
was pelleted and resuspend in 100 mL ChIP buffer. Nuclear lysates were further subjected to sonication to break nuclear membrane
using a 120 Sonic Dismembrator (Fisher Scientific) at 4C for 3 cycles, cyclingON for 10 s andOFF for 30 s at 50%amplitude. Approx-
imately 10 mg of digested, cross-linked chromatin and 5 mg of antibody (BAF155, Cell Signaling Technologies, 11956; PU.1, Cell
Signaling Technologies, 2258; H3K27me3, Millipore,07-449) were used per immunoprecipitation. IP samples were incubated over-
night at 4C with rotation, followed by 30 mL of protein G Magnetic Beads per IP reaction, and incubated for an additional 2 hr at 4C
with rotation. After elution of chromatin from the antibody/protein G magnetic beads, reverse cross-link performed by adding 6 mL
5 M NaCl and 2 mL proteinase K per IP, and incubating for 6 hr at 65C. Immunoprecipitated DNA fragments were isolated using spin




columns provided by the kit and subjected to qPCR with appropriate primers indicated in Table S2. Rabbit IgG (Cell Signaling Tech-
nologies, 2729) was used as a negative control. Quantitative PCR was performed in triplicate from 3 independent experiments, and
data were normalized to input values.
Tissue processing for flow cytometry
YS were collected between E8.25-10.5, and brain rudiments collected between E9.5-10.5. To obtain single-cell suspension, tissues
were incubated in Hank’s balanced salt solution (HBSS) containing 0.2 mg/ml collagenase type IV (Worthington), 100 U/ml deoxy-
ribonuclease I (Worthington) and 5% FBS at 37C for 1 h with tubes inverted every 5 to 10 min. Tissues were further dissociated by
gently passing through a 20G needle 5 to 10 times. Cells were pelleted and resuspend in 0.3-1 mL IMDMmedia with 10% FBS. Cells
were then passed through a 70 mm cell strainer and counted for viability.
Flow cytometry and cell sorting
Single cell suspensions were centrifuged at 400 g for 5 min, resuspended in 200 mL staining buffer (1X PBS, 1% BAS, 2 mM EDTA),
placed in 5ml round-bottom tubes, and immunolabeled for FACS analysis. Before immunostaining, cell suspensions were pre-incu-
bated with diluted (1:50) purified anti-CD16/32 (clone: 93, Biolegend, 101302) for 10 min on ice to block non-specific binding to Fc-
receptors. Next, antibodies were added and incubated for 40 min on ice. Where appropriate, cells were further incubated with strep-
tavidin conjugates for 20 min. All antibodies used can be found in key resources table. All FACS analyses were carried out on LSR
Fortessa or Fortessa X-20 (BD Biosciences). Cell sorting was performed on FACS Aria II (BD Biosciences) sorter using 85 mm nozzle.
All data were analyzed using FlowJo10 software (Tree Star).
Quantitative real-time reverse transcription PCR (qRT-PCR)
Total RNA from YS was prepared with RNeasy Micro/Mini Kit (QIAGEN), and reverse-transcribed into cDNA with qScript cDNA
SuperMix (101414-106, Quanta) according to the manufacturer’s protocol. Gene expression was measured by quantitative real-
time PCR with primers indicated in Table S3. Gene expression levels were normalized to b-actin.
Single-cell RNA sequencing
An equal number of E9.5 and E10.5 WT YS were combined and dissociated with 0.25% collagenase at 37C for 30 minutes. Cells
were briefly stored at80C in 90%FBS and 10%DMSO. Cells were thawed, washedwith PBS, and stainedwith TER-119 antibody.
Dead cells and TER-119+ cells were excluded by sorting to enrich live non-erythroid cells. Single cell suspension at 300 cells/mL in
PBS were subjected to Chromium 10x Genomics library construction and HiSeq2500 sequencing (The Genome Technology Access
Center, Washington University in St. Louis).
ATAC-seq library generation, sequencing, and mapping
For ATAC-seq library generation, approximately 50,000 cKIT+ cells were isolated fromWT and Baf155CKO YS using FACS sorter as
described above. ATAC-seq libraries were generated following theOmni-ATACprotocol (Corces et al., 2017) with the followingmodi-
fication: Cells were harvested by centrifuging at 500 g for 5 minutes at 4C. Supernatant was carefully aspirated and cells were
washed once with cold PBS. Cell pellets were lysed in 100 ml of ATAC-seq RSB (10 mM Tris pH 7.4, 10 mM NaCl, 3 mMMgCl2) con-
taining 0.1%NP40, 0.1%Tween-20, and 0.01%Digitonin by pipetting up and down and incubating on ice for 3minutes. Next, 1mL of
ATAC-seq RSB containing 0.1%Tween-20was added andmixedwith the lysis reaction. Nuclei were pelleted by centrifuging at 800 g
for 5 minutes at 4C. Supernatant was carefully removed, and nuclear pellets were resuspended in 20 ml 2x TD buffer (20 mM Tris pH
7.6, 10mMMgCl2, 20%Dimethyl Formamide). Nuclei were counted using trypan blue. Approximately 50,000 nuclei were transferred
to 25 mL of 2x TD buffer. 25 ml of transposition mix (2.5 ml transposase (100 nM final), 16.5 ml PBS, 0.5 ml 1% digitonin, 0.5 ml 10%
Tween-20, and 5 ml H2O) was then added to the nuclei. Transposition reactions were mixed and incubated at 37
C for 30 min gently
tapping every 10 min to mix. Reactions were cleaned up with Zymo DNA Clean and Concentrator 5 columns. ATAC-seq library was
prepared by amplifying the DNA for 9 cycles on a thermal cycler. The PCR reaction was purified with AMPure XP beads using double
size selection following the manufacture’s protocol, in which 27.5 ml beads (0.55x sample volume) and 50 ml beads (1.5x sample vol-
ume) were used based on 50 ml PCR reaction. ATAC-seq libraries were quantitated by Qubit assays. Paired-end ATAC-seq libraries
were sequenced on an Illumina NextSeq 500 machine. The reads were de-multiplexed by using sample-specific index sequences.
Nextera adaptor sequences were trimmed by using cutadapt (Martin, 2011) version 1.11. The trimmed reads were mapped to the
mouse genome sequence by using bowtie2 (Langmead and Salzberg, 2012) version 2.3.4.1 with the following parameters: –local
-k 4 -X 2000 –mm. Secondary alignment, multiply mapped reads, and PCR duplicated reads were removed from the total aligned
reads.
QUANTIFICATION AND STATISTICAL ANALYSIS
scRNA-seq bioinformatics analyses
The sequenced reads were mapped to the GRCm38 assembly using Cell Range 2.0.1 (10x Genomics). Sample demultiplexing, bar-
code processing, and single-cell 30 counting was performed using the Cell Ranger Single-Cell Software Suite (10x Genomics).




Cellranger count was used to align samples to themm10 reference genome, quantify reads, and filter readswith a quality score below
30. The resultant files were input into Seurat for normalization across all samples andmerging. The Seurat package in R was used for
subsequent analysis (Butler et al., 2018). Cells withMitochondrial content greater than 5 percent were removed for downstream anal-
ysis. Data were normalized using a scaling factor of 10,000, and nUMI was regressed with a negative binomial model. Principal
component analysis was performed using the top 3000 most variable genes and t-SNE analysis was performed with the top 15
PCAs. Clustering was performed using the FindClusters function which works on K-nearest neighbor (KNN) graph model with the
granularity ranging from 0.1-0.9 and selected 0.6 for the downstream clustering. For identifying the markers for each cluster, we per-
formed differential expression of each cluster against all other clusters identifying negative and positive markers for that cluster
Identification of ATAC peaks
Filtered aligned ATAC-seq reads were used to map to the transposon insertion sites, and ATAC peaks were called from those inser-
tion sites. First, ATAC-seq reads mapped to mitochondrial DNA were removed from the aligned reads. Both ends of the paired-end
reads were then treated as two Tn5 insertion sites. Tn5 insertion sites were adjusted to reflect the actual binding center of transpo-
sons as follows. All reads mapped to the + strand were offset by +4 bp, and all reads mapped to the  strand were offset by 5 bp.
The ATAC peaks were identified from these insertion sites by using the MACS2 (Zhang et al., 2008) version 2.1.1 callpeak function
with the following parameters: -gmm --keep-dup all -B --SPMR --nomodel --extsize 73 --shift -37 -p 0.01 --call-summits. The ATAC-
seq signals were visualized on the WashU Epigenome Browser (Zhou et al., 2011) as fold change over background using bedGraph
tracks generated by using the MACS2 bdgcmp function with the following parameter: -m FE.
Identification and analyses of DARs
To identify DARs, DiffBind (Ross-Innes et al., 2012) version 2.6.6 was used on the union set of ATAC peaks with the following param-
eters:minOverlap = 1, fragmentSize = 1, summits = 0. DARswere defined as the ATACpeakswith fold change > 2 andP-value < 0.05.
Unaffected accessible regions were defined as the ATAC peaks that are present both wild-type and Baf155 CKO cells and that are
also with fold change < 1.1 and P-value > 0.05 from DiffBind. Heatmaps of ATAC-seq signal levels of DARs along with their neigh-
boring regions were plotted by using deepTools (Ramı́rez et al., 2016). Gene Ontology enrichment analysis on DARs and unaffected
regions were performed using GREAT (McLean et al., 2010) version 4.0.4. Motif enrichment analysis on DARs was performed using
HOMER (Heinz et al., 2010) version 4.8. HOMER scanned the sequences of DARs for knownmotifs, and calculated enrichment score
P-values using a binomial test. The heatmap of the selected known motifs were plotted using fold enrichment against the back-
ground. HOMER also discovered de novo motifs with their best matches to a known motif in DARs.
Statistics
GraphPad Prism 8 software was used for performing statistical analysis and generating graphs/plots. Data are presented as mean
with standard deviation for all the measurements. All experimental data were reliably reproduced in two or more individual biological
replicates. Details of the statistical tests performed are given in the respective figure legends. p < 0.05 was considered statistically
significant.
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Figure S1 (Related to Figure 1). Baf155 CKO mice show defects in myeloid and definitive erythroid lineage 
development. 
(A) Flow cytometry analysis of erythroid cells (CD45-TER119+), endothelial cells (EC, CD45-CD31+), myeloid 
(CD45+CD11b+) and microglia (CD45+CD11b+F4/80+) from E10.5 Tie2-Cre;Rosa26-floxed stop tdTomato YS and 
brain rudiment. (B) A representative flow cytometric analysis of E9.5 yolk sac (YS) primitive erythroid cells (CD45-
Ter119+), endothelial cells (CD45-CD31+), myeloid cells (CD45+CD11b+), macrophages (CD45+F4/80+), and brain 
microglia (CD45+CX3CR1+ CD11b+) in wild type (WT) and Baf155 CKO mice is shown in the upper panel. The 
percentage of each population is shown in the bottom panel. At least 4 biological replicates in 2 independent 
experiments for either genotype were analyzed, each representing an individual YS. Data are presented as mean ± 
SD. Student’s t-test. ns. not significant, **p<0.005. ***p<0.001. ****p<0.0001.  (C) A representative flow 
cytometry analysis of microglia (CD45+CX3CR1+    CD11b+) from E10.5 WT and Baf155 CKO brain rudiments is 
shown in the left panel and percentage of microglia is shown on the right. At least 6 biological replicates for either 
genotype, with each replicate consisting of an individual embryo. Data are presented as mean ± SD. Student’s t-test. 
****p<0.0001. (D) qRT-PCR analysis of indicated gene expression in E10.5 WT and Baf155 CKO YS. Data from 
at least 2 biological replicates, with each replicate consisting of an individual YS. Data are presented as mean ± SD. 


































































































































































































































Figure S2 (Related to Figure 2). Baf155 is required for myeloid and definitive erythroid lineage 
differentiation from EMPs. 
(A) An example of flow cytometry analysis of a Kit+CD41+CD16/32+ population from E9.5 WT (top) and Baf155 
CKO (bottom) YS (left panel). Percentage of Kit+CD41+CD16/32+ per YS is shown on the right. Data are presented 
as mean ± SD from 26 WT and 6 Baf155 CKO biological replicates from 4 independent experiments. Student’s t-
test. ns. not significant, ***p<0.001. (B) An example of flow cytometry analysis of a CD41+CD16/32+ population 
from E9.5 WT and Baf155 CKO YS (left). Percentage of CD41+CD16/32+ cells per YS is shown on the right. Data 
are presented as mean ± SD from 26 WT and 6 Baf155 CKO biological replicates in 4 independent experiments. 
Student’s t-test. ns. not significant, ****p<0.0001. (C) An example of flow cytometry analysis of a 
Kit+CD41+CD16/32+ population from E10.5 WT and Baf155 CKO YS (left). Percentage of Kit+CD41+CD16/32+ 
cells per YS is shown on the right. Data are presented as mean ± SD from 26 WT and 10 Baf155 CKO biological 
replicates in 4 independent experiments. Student’s t-test. ns. not significant, ****p<0.0001. (D) An example of flow 
cytometry analysis of a CD41+CD16/32+ population from E10.5 WT and Baf155 CKO (left) YS. Percentage of 
CD41+CD16/32+ cells per YS is shown on the right. Data are presented as mean ± SD from 28 WT and 13 Baf155 
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Figure S3 (Related to Figure 3). scRNA-seq of wild type yolk sac shows 7 independent cell populations. 
 (A) t-SNE projection of all cells, showing 7 different clusters. (B-H) Expression of the indicated marker genes 
for specific cell states/lineage fates in the t-SNE. B, endothelial cells; C, primitive and definitive erythroid cells; 
D, primitive erythroid cells; E, definitive erythroid cells; F, myeloid cells; G, EMPs; and H, pericytes and 
smooth muscle cells. (I) The expression of primitive and definitive erythroid cell markers in the t-SNE. (J) The 
expression of myeloid cell markers in the t-SNE. (K) The expression of EMP marker genes in the t-SNE. (L) The 
expression of pericytes and smooth muscle cell markers in the t-SNE. (M) CD34 and Baf155 expression in each 
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Kit Itga2b Gata2 Cd34 Tal1
-Log10 (p) % DARsMotif Best Match
2,326 60.08% Spi 1 (ETS)
407 25.24% Fosl 1 (AP-1)
253 8.50% Spi1-IRF (ETS:IRF)
244 27.93% Runx (Runt)
122 14.86% CEBPE (CEBP)
2,231 27.86% Ctcfl (Zf)
157 18.54% Erg (ETS)
74 26.44% Pol
59 10.73% Tead (TEA)
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Figure S4 (Related to Figure 4). Baf15  CKO EMPs have reduced chromatin accessibility at the myeloid and 
EryD gene loci. 
(A) Gating strategy for isolating cKIT+ cells from WT (top) and Baf155 CKO (bottom) YS. (B) Top 5 de novo 
transcription factor motifs enriched in the DARs with reduced signals in Baf155 CKO EMPs (top) and in the 
unaffected regions (bottom). (C) Epigenome browser views of myeloid gene loci. (D) Epigenome browser views of 
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Figure S5 (Related to Figure 5). BAF155 interacts with PU.1 and is recruited to its target genes. 
(A) Nuclear extracts from MEF cells overexpressing Flag-Baf155 and Pu.1 or Flag-Baf155 and HA-Pu.1 were 
subjected to immunoprecipitation with anti-FLAG (left) or anti-HA affinity gel (right) and immunoblotted with 
BAF155, PU.1, BRG1, UTX and P300. Protein A agarose pull down serves as a negative control. (B) Epigenome 
browser views of selected myeloid and negative control genomic regions, and unaffected ETS regions between WT 
and Baf155 CKO YS EMPs (top panel). ChIP-qPCR showing enrichment of H3K27me3 binding at selected myeloid 
gene loci (highlighted regions in top panel, 1-6), negative control gene loci (highlighted regions in top panel, 2n and 
6n) and unaffected ETS regions (highlighted regions in top panel, UER1 and UER2) between E10.5 WT and Baf155 
CKO YS (bottom panel). qPCR primers and genomic locations are provided in Table S3. Sixty-three WT yolk sacs 
and 21 Baf155 CKO yolk sacs were pooled together to perform ChIP. The average from three independent PCR data 
is shown. (C) qRT-PCR analysis of Cx3cr1, Irf8 and Csf-1r gene expression from E9.5 wild type yolks sac with or 
without SBE- -CD (GSK126 vehicle) treatment. Data from at least six biological replicates for each group. Data 
are presented as mean ± SD. Student’s t-test. ns. not significant. (D) qRT-PCR analysis of Gata2, Scl and Kit gene 
expression from E9.5 WT and Baf155 CKO YS with or without GSK126 treatment. Gene expression was 
normalized to untreated WT mean values. Data from at least 4 biological replicates for each genotype. Data are 
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